Pesquisar
AIM ImmunoTech Inc
AIMAdicionar à lista de desejos
0.279USD
-0.017-5.84%
Fechamento 06/30, 16:00（ET）Cotações atrasadas em 15 min
2.29MValor de mercado
PerdaP/L TTM
Mais detalhes de AIM ImmunoTech Inc Empresa
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Informações de AIM ImmunoTech Inc
Código da empresaAIM
Nome da EmpresaAIM ImmunoTech Inc
Data de listagemJul 12, 1996
CEOEquels (Thomas K)
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço2117 Sw Highway 484
CidadeOCALA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal32801
Telefone13524487797
Sitehttps://aimimmuno.com/
Código da empresaAIM
Data de listagemJul 12, 1996
CEOEquels (Thomas K)
Executivos da empresa AIM ImmunoTech Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de AIM ImmunoTech Inc?
Os cinco principais acionistas de AIM ImmunoTech Inc são: Mr. Thomas K. Equels, Esq., J.D.
Quantas instituições possuem ações da AIM ImmunoTech Inc (AIM)?
Em 2026Q1, 57 instituições possuíam ações da AIM ImmunoTech Inc, com valor de mercado aproximado de 105.74K, representando 1.30% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -74291.00.
